BioNTech, first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below “typical market rates” and would differentiate pricing between countries or regions – Reuters reports.
According to Reuters, the German biotech firm’s strategy head Ryan Richardson said the price tag of the vaccine, which is co-developed with Pfizer and which has yet to win regulatory approval, would reflect the financial risks that its private-sector investors have incurred.
At this point, BioNTech has declined to elaborate on the different price tags across different regions of the world.
